

**Supplementary Table 1. Adverse events of eradication medications
(intention-to-treat set), *n* (%)**

Variable	7-day PC-BMT (<i>n</i> = 119)		14-day PC-BMT (<i>n</i> = 118)		14-day P-BMT (<i>n</i> = 117)	
	<i>n</i>	Frequency	<i>n</i>	Frequency	<i>n</i>	Frequency
Adverse event	23 (19.3)	34	36 (30.5)	51	32 (27.4)	40
Mild	20 (16.8)	30	28 (23.7)	35	29 (24.8)	34
Moderate	3 (2.5)	4	10 (8.5)	16	4 (3.4)	4
Severe	0 (0.0)	0	0 (0.0)	0	1 (0.9)	2
Gastrointestinal disorders	19 (16.0)	23	25 (21.2)	30	28 (23.9)	3
Nausea	15 (12.6)	15	16 (13.6)	16	16 (13.7)	1
Diarrhea	2 (1.7)	2	5 (4.2)	5	6 (5.1)	6
Dyspepsia	2 (1.7)	2	3 (2.5)	3	3 (2.6)	3
Vomiting	3 (2.5)	3	3 (2.5)	3	2 (1.7)	2
Abdominal pain, upper	0 (0.0)	0	1 (0.9)	1	2 (1.7)	2
Abdominal distension	1 (0.8)	1	0 (0.0)	0	1 (0.9)	1
Dry mouth	0 (0.0)	0	1 (0.9)	1	0 (0.0)	0
Acid reflux	0 (0.0)	0	1 (0.9)	1	0 (0.0)	0
Retching	0 (0.0)	0	0 (0.0)	0	1 (0.9)	1
Tongue discomfort	0 (0.0)	0	0 (0.0)	0	1 (0.9)	1
Nervous system disorders	8 (6.7)	9	9 (7.6)	1	5 (4.3)	5
Dizziness	4 (3.4)	4	3 (2.5)	3	4 (3.4)	4
Headache	5 (4.2)	5	5 (4.2)	5	0 (0.0)	0

Migraine	0 (0.0)	0	1 (0.9)	1	1 (0.9)	1
Lethargy	0 (0.0)	0	1 (0.9)	1	0 (0.0)	0
Psychiatric disorders	0 (0.0)	0	3 (2.5)	3	2 (1.7)	2
Helplessness	0 (0.0)	0	3 (2.5)	3	2 (1.7)	2
Skin disorders	1 (0.8)	1	2 (1.7)	2	1 (0.9)	1
Rash	1 (0.8)	1	1 (0.9)	1	1 (0.9)	1
Urticaria	0 (0.0)	0	1 (0.9)	1	0 (0.0)	0
Metabolism disorders	0 (0.0)	0	3 (2.5)	3	0 (0.0)	0
Decreased appetite	0 (0.0)	0	3 (2.5)	3	0 (0.0)	0
General disorders and administration site conditions	1 (0.8)	1	1 (0.9)	1	0 (0.0)	0
Asthenia	1 (0.8)	1	1 (0.9)	1	0 (0.0)	0
Infectious disorders	0 (0.0)	0	1 (0.9)	1	0 (0.0)	0
Herpes zoster	0 (0.0)	0	1 (0.9)	1	0 (0.0)	0
Musculoskeletal disorders	0 (0.0)	0	1 (0.9)	1	0 (0.0)	0
Myalgia	0 (0.0)	0	1 (0.9)	1	0 (0.0)	0

Frequency indicates the number of adverse events. P-BMT:Proton pump inhibitor-based bismuth-containing quadruple regimen; PC-BMT:Potassium-competitive acid blocker-based bismuth-containing quadruple regimen.